AI Market Mood: Stock Dashboard
SMMT
Fundamental
Company: Summit Therapeutics Inc
Sector: Healthcare
Industry: Biotechnology
Country: USA
Exchange: NASD
Index: -
P/E: -
EPS (ttm): -1.24
Insider Own: 86.17%
Shs Outstand: 744.44M
Perf Week: -3.64%
Market Cap: 12.99B
Forward P/E: -
EPS next Y: -0.91
Insider Trans: 0.20%
Shs Float: 102.73M
Perf Month: -2.24%
Enterprise Value: 12.76B
PEG: -
EPS next Q: -0.24
Inst Own: 14.08%
Short Float: 34.80%
Perf Quarter: -15.34%
Income: -921.61M
P/S: -
EPS this Y: -324.58%
Inst Trans: 5.74%
Short Ratio: 12.57
Perf Half Y: -17.50%
Sales: 0.00M
P/B: 67.72
EPS next Y Percentage: 30.61%
ROA: -241.08%
Short Interest: 35.75M
Perf YTD: -1.99%
Book/sh: 0.26
P/C: 54.38
EPS next 5Y: -
ROE: -292.49%
52W High: 36.91 -52.61%
Perf Year: -9.28%
Cash/sh: 0.32
P/FCF: -
EPS past 3/5Y: 31.56% -10.52%
ROIC: -472.69%
52W Low: 15.55 12.48%
Perf 3Y: 355.47%
Dividend Est.: -
EV/EBITDA: -
Sales past 3/5Y: - -
Gross Margin: -
Volatility W: 2.58%
Volatility M: 4.26%
Perf 5Y: 191.50%
Dividend TTM: -
EV/Sales: -
EPS Y/Y TTM: -348.63%
Oper. Margin: -
ATR (14): 0.74
Perf 10Y: 71.98%
Dividend Ex-Date: -
Quick Ratio: 3.80
Sales Y/Y TTM: -
Profit Margin: -
RSI (14): 46.02
Recom: 1.38
Dividend Gr. 3/5Y: - -
Current Ratio: 3.80
EPS Q/Q: -302.84%
SMA20: -1.86%
Beta: -1.52
Target Price: 34.00
Payout: -
Debt/Eq: 0.03
Sales Q/Q: -
SMA50: -3.02%
Rel Volume: 0.51
Prev Close: 17.78
Employees: 159
LT Debt/Eq: 0.01
Earnings: Oct 20 BMO
SMA200: -20.00%
Avg Volume: 2.84M
Price: 17.49
IPO: Mar 05, 2015
Option/Short: Yes / Yes
EPS/Sales Surpr.: -82.25% -
Trades:
Volume: 1,458,392
Change: -1.63%
Technical:
Latest News:
Citigroup Initiates Coverage of Summit Therapeutics (SMMT) with Buy Recommendation very bullish
SMMT
Summary: Citigroup initiated coverage of Summit Therapeutics with a Buy recommendation, projecting a 53.67% upside potential. Various funds and institutions are increasing their positions, with a bullish sentiment indicated by the put/call ratio of 0.35.
Full article2024-05-08T17:42:16Z